Efficacy and prognosis of PD-1 inhibitors, trastuzumab, and first-line chemotherapy for HER-2-positive advanced gastric cancer in real-world study

被引：0
|
作者：
Liu, B. [1 ]
Tao, Y. [1 ]
Ke, Y. [1 ]
Rao, W. [1 ]
Liu, Q. [1 ]
机构：
[1] Nanjing Univ, Affiliated Drum Tower Hosp, Med Sch, Comprehens Canc Ctr, Nanjing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.193
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
169P
引用
收藏
页码：S1470 / S1470
页数：1
相关论文
共 50 条
  • [1] First-line PD-1 inhibitors combination therapy for patients with advanced cholangiocarcinoma: A retrospective real-world study
    Ye, Ziqi
    Zhang, Yanfang
    Chen, Jie
    Wang, Xiaoting
    Hong, Yun
    Zhao, Qingwei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 120
  • [2] Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer
    Xu, Mengli
    Meng, Xiangrui
    Lu, Yao
    Wang, Feng
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (02) : 548 - 558
  • [3] Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study
    Zhu, Chengpei
    Li, Hu
    Yang, Xiaobo
    Wang, Shanshan
    Wang, Yunchao
    Zhang, Nan
    Wang, Yanyu
    Xue, Jingnan
    Zhang, Longhao
    Ning, Cong
    Yang, Xu
    Xun, Ziyu
    Chao, Jiashuo
    Long, Junyu
    Sang, Xinting
    Zhu, Zhenyu
    Zhao, Haitao
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (09) : 2949 - 2960
  • [4] Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study
    Chengpei Zhu
    Hu Li
    Xiaobo Yang
    Shanshan Wang
    Yunchao Wang
    Nan Zhang
    Yanyu Wang
    Jingnan Xue
    Longhao Zhang
    Cong Ning
    Xu Yang
    Ziyu Xun
    Jiashuo Chao
    Junyu Long
    Xinting Sang
    Zhenyu Zhu
    Haitao Zhao
    Cancer Immunology, Immunotherapy, 2023, 72 : 2949 - 2960
  • [5] Real world data and biomarker analysis of the efficacy and safety of PD-1 inhibitor combined with chemotherapy in first-line treatment of advanced gastric cancer.
    Ma, Xiaoting
    Ou, Kai
    Yang, Wenwei
    Cao, Biyang
    Yang, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 342 - 342
  • [6] Efficacy of rechallenge after first-line immunotherapy for advanced gastric cancer: A retrospective real-world study
    Guo, Mengya
    Zhao, Wenhui
    Chen, Yue
    Zou, Dan
    Peng, Weiwei
    Sha, Huanhuan
    Zhou, Guoren
    Fang, Ying
    Shen, Bo
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [7] Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric cancer in real-world patients: Updated analysis.
    Shimozaki, Keitaro
    Fukuda, Koshiro
    Ooki, Akira
    Nakayama, Izuma
    Yoshino, Koichiro
    Udagawa, Shohei
    Fukuoka, Shota
    Osumi, Hiroki
    Ogura, Mariko
    Wakatsuki, Takeru
    Takahari, Daisuke
    Shinozaki, Eiji
    Chin, Keisho
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 341 - 341
  • [8] Efficacy and survival of anti-PD-1 antibody in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy as first-line treatment of HER2-positive metastasis gastric adenocarcinoma: a retrospective study
    Deng, Ting
    Li, Danyang
    Yang, Yuchong
    Wang, Feixue
    Bai, Ming
    Liu, Rui
    Li, Hongli
    Ba, Yi
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [9] Efficacy and safety of PD-1 inhibitors in combination with chemotherapy versus chemotherapy as first and second line treatment in advanced gastric and gastroesophageal junction cancer: Preliminary data from a real-world setting.
    Hu, Yi
    Li, Tao
    Zhang, Fan
    Zhao, Lei
    Zhao, Xiaochen
    Cai, Shangli
    Zhao, Jing
    Jiao, Shun Chang
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting
    Moser, Sarah Sharman
    Apter, Lior
    Livnat, Idit
    Ginsburg, Roni
    Yarden, Adva
    Drori, Michal
    Drizon, Anat
    Chodick, Gabriel
    Siegelmann-Danieli, Nava
    BREAST CANCER-TARGETS AND THERAPY, 2024, 16 : 105 - 116
12345